MedTrace Logo

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

NCT06555068 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 528

Last updated 2025-06-22

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, or HRS-1358 for advanced unresectable or metastatic breast cancer

Conditions

  • Advanced Unresectable or Metastatic Breast Cancer

Interventions

DRUG

HRS-6209 in Combination with Fulvestrant

HRS-6209 in Combination with Fulvestrant

DRUG

HRS-6209 in Combination with HRS-1358

HRS-6209 in Combination with HRS-1358

DRUG

HRS-6209 in Combination with Letrozole

HRS-6209 in Combination with Letrozole

DRUG

HRS-6209 in Combination with HRS-8080

HRS-6209 in Combination with HRS-8080

DRUG

HRS-6209 in Combination with HRS-1358

HRS-6209 in Combination with HRS-1358

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-12
Primary Completion
2025-12-31
Completion
2026-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06555068 on ClinicalTrials.gov